Drug intelligence / Profile preview

Otijan

Development stage
Unknown
Lead developer
Jainson Biotech
Modality
Small Molecules
Administration
Otic
01

Overview

Otijan is a combination ear drop formulation developed by Jainson Biotech for the treatment of allergic, inflammatory, and infectious conditions of the middle and external ear, including otorrhea. It contains four active ingredients: neomycin sulfate (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit), betamethasone (a topical corticosteroid that acts as a glucocorticoid receptor agonist to reduce inflammation and swelling), clotrimazole (a broad-spectrum imidazole antifungal that inhibits lanosterol 14-alpha-demethylase to disrupt fungal cell membrane synthesis), and lignocaine hydrochloride (a local anesthetic that blocks voltage-gated sodium channels to provide symptomatic pain relief).

Brand names
Otijan
Other names
Betamethasone + Clotrimazole + Lignocaine + Neomycin Ear Dropsbetamethasone + clotrimazole + lidocaine + neomycinbetamethasone + clotrimazole + lignocaine + neomycin
02

Targets

Bacterial RibosomeGR (Glucocorticoid receptor)CYP51A1 (Sterol 14α-demethylase)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Otijan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otijan.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call